Table 3.
Response by Time on Therapy by ITT
| n/N (%) | |||
|---|---|---|---|
| 6 month | 12 month | 18 month | |
| ITT Rate CCyR | |||
| Overall | 36/50 (72) | 29/46 (63) | 26/44 (59) |
| Imatinib | 19/30 (63) | 14/29 (48) | 14/28 (50) |
| 2GTKI | 17/20 (85) | 15/17 (88) | 12/16 (75) |
| ITT Rate MMR | |||
| Overall | 15/50 (30) | 23/46 (50) | 22/44 (50) |
| Imatinib | 3/30 (10) | 11/29 (38) | 13/28 (46) |
| 2GTKI | 12/20 (60) | 12/17 (71) | 9/16 (56) |
CCyR, Complete Cytogenetic Response; MMR, Major Molecular Response; 2GTKI, Second Generation Tyrosine Kinase Inhibitor
- Patients lost to follow-up or who did not reach the given time point for analysis were excluded from the ITT denominator
- For the evaluable population only, response rates are higher. For example at 18 months, CCyR is 81% for all patients (n=32), 82% for imatinib (n=17) and 80 for 2GTKI (n=15). Corresponding rates for MMR are 81% (n=27), 100% (n=13) and 64% (n=14), respectively.